

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 2

Abstract

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 3

Introduction

 Alcohol use is the third leading preventable cause of death in the United States [1, 2]. Heavier alcohol use has consistently been reported to be associated with increased risk for numerous chronic diseases and conditions, such as liver diseases [3, 4, 5, 6]. With respect to liver diseases, alcohol-attributable mortality from liver cirrhosis, an advanced stage of liver fibrosis, accounted for 47.9 percent of all liver cirrhosis deaths worldwide (493,300 deaths) [3]. Liver steatosis (fatty liver) is detected in 90% of people with heavy alcohol consumption [5, 7]. Although liver steatosis is usually asymptomatic [5], it can progress to liver inflammation and liver cirrhosis [8]. Though the relationship between heavy alcohol consumption and liver diseases are an established public health concern, it is unclear how reducing or cessating from alcohol consumption is associated with prevention of liver outcomes progression, warranting further investigation. Alcohol use is prevalent among persons living with HIV (PLWH) [9, 10], which is also associated with incidence of liver disease [9]. Liver disease is one of the leading causes of death among PLWH [10]. A recent cohort study [11] noted that the prevalence of liver diseases among PLWH were 10 times higher compared with HIV-negative counterparts. A systematic review [12] reported that the prevalence of non-alcoholic fatty liver disease (NAFLD) and fibrosis were 35% and 22% in PLWH, respectively. Moreover, HIV is associated with steatosis [13] and chronic systemic inflammation, which may place PLWH at higher risk for developing liver

disease [14].

 A review article [15] highlighted the need of intervention for drinking reduction and for better understanding of HIV-related health outcomes at individual and policy levels. Contingency 87 management (CM) is one drinking intervention that has been effective for alcohol reduction [16, 88 17]. CM involves providing financial or other incentives for meeting a treatment goal or, a negative consequence if the individual is unable to meet this goal. However, there is limited published information about how short-term alcohol interventions, such as CM, may impact liver disease, especially in PLWH and in the persons without severe liver disease at baseline. Among two populations of "healthy" individuals who drank moderately-to-heavily, short-term abstinence (one month) from alcohol resulted in significantly reduced serum alanine

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 4

 aminotransferase (ALT) and gamma-glutamyl transferase (GGT), both indicating improvement in liver function [18, 19]. The study outcomes for these two studies were assessed only at 30- days, so it is unclear if these benefits persisted after 30-days. Further, it is unclear whether any benefits of alcohol reduction extended to prevent liver fibrosis and steatosis progression, key manifestations of both alcoholic-related liver disease (ALD) and NAFLD. The primary objective of this study was to determine whether liver fibrosis and steatosis, measured using FibroScan, change significantly with alcohol reduction from a CM intervention, over three time periods (baseline, 30-days, and 90-days) among older adults who drink heavily with or without stratified liver fibrosis and steatosis values at baseline. In the current study, the fibrosis-4 (FIB-4) index [20] was analyzed as an additional liver outcome measure. We hypothesized that the patterns of change in liver outcome measures would differ in alcohol consumption categories (*i.e. quit/reduced drinking vs. continued heavy drinking*) during the course of study, observed by an interaction effect between alcohol intake and time from an

analysis. This study would increase knowledge and empirical evidence on the prevention of

progression in liver abnormalities, fibrosis and steatosis before and after the initiation of a

drinking abstinence program.

Materials and Methods

Study Participants

 This prospective study included older adults (aged 50 to 75 years) with heavy drinking (≥14 drinks/week for women, ≥21 drinks/week for men) at the baseline, living with or without HIV infection, and were enrolled in a clinical trial of drinking-reduction from 12/11/2017 to 11/16/2021. A description of the methods of drinking-reduction program, "30-Day Challenge Study," is available in ClinicalTrials.gov registry and is shown in Fig 1. The trial was registered under ClinicalTrials.gov with registry date and number (11/27/2017) (NCT03353701) respectively. In brief, the "30-Day Challenge Study" used CM with financial incentives to measure the impact of changes in alcohol consumption on changes in neurocognitive disorders, liver fibrosis, and other HIV-related comorbidities. All procedures in the "30-Day Challenge Study" were approved by the central Institutional Review Board at University of Miami (Study

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 5

Number: 20170396). All study participants provided informed consent prior to participation. All

- methods were carried out in accordance with relevant guidelines and regulations.
-

Fig 1. Timeline of the 30-Day Challenge Study. The data used in this analysis come from the

- baseline, 30-day, and 90-day follow-up visits, with measures included listed below each
- timepoint. The contingency management (CM) period began at Baseline and ended at the 30-day
- follow-up.
-
- This study analyzed data from the baseline, 30-day follow-up (post CM), and 90-day follow-up
- visits. At the time of data retrieval (12/07/2021), the dataset included 56 participants, but 10 were
- excluded from the analysis due to missing baseline (*n* = 1), or missing both 30-days and 90-days
- 135 follow-up data on alcohol consumption $(n = 8)$, or AST level $(n = 1)$. In summary, data were
- included from 46 participants with complete information on alcohol intake and liver outcome

measures at baseline and at least one follow-up visit.

Outcome Measures

 The outcome variables included the changes from baseline values on liver fibrosis measured by 141 transient elastography (TE), and steatosis measured by controlled attenuation parameter (CAP), respectively. These quantitative measures were obtained using a FibroScan (Echosens, Paris, France) from baseline, 30-days, and 90-days. Additionally, the fibrosis-4 (FIB-4) index [20], a validated noninvasive test alternative to liver biopsy, was considered to further investigate the trend in liver fibrosis, calculated as,

$$
FIB-4 = \frac{Age \times AST}{platelet Count \times \sqrt{ALT}}
$$

147 where $AST =$ aspartate aminotransferase and $ALT =$ alanine aminotransferase. Hence, the changes from baseline value on FIB-4 was also considered as an outcome variable.

Main Predictor

Although abstinence is often regarded as the primary endpoint in alcohol use disorder treatment,

the prior studies [21, 22] have shown that reduced alcohol consumption at any level has also

been linked to improved health outcomes. Thus, we decided to examine alcohol consumption as

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 6

 a dichotomous variable rather than a 3-level categorical variable. Alcohol intake categories were derived from the Alcohol Timeline Followback (TLFB) [23] data in the previous 30-days. *Heavy drinking* was defined as consuming more than 7 drinks per week for females and more than 14 drinks per week for males, based on the National Institute on Alcohol Abuse and Alcoholism (NIAAA) guideline [24]; *reduced drinking* was definined as drinking level that did not qualify as heavy drinking; 3) *quit drinking* if a participant did not drink during 30 days. In this study, reduced and quit drinking categories are combined for the analysis.

Covariates

HIV diagnosis (negative or positive), body mass index (BMI), sex at birth (female or male), age

in continuous scale, and hepatitis C (HCV) were included as covariates in later multivariable

analysis. HCV antibody test was conducted at baseline and classified as positive or negative.

HCV was included as a covariate, as earlier research showed that the alcohol consumption is

related to the transmission of both HIV and HCV [25]. BMI was broken down into three

168 categories: underweight or normal (BMI $<$ 25.0), overweight (25.0 \leq BMI $<$ 30.0), and obese

169 (BMI \geq 30) based on the Centers for Disease Control and Prevention classification of

overweight and obesity guideline [26]. Previous studies have shown that obesity is the important

risk factor for NAFLD [8, 27].

Statistical Methods

 A linear mixed-effects model with random intercept was used to determine the changes in FibroScan (TE and CAP), and FIB-4 score while accounting for within-subject correlations. An unstructured covariance matrix was used. The change in log-transformed values of TE and FIB-4 were used as outcomes after examining residual diagnostics and standard model assumptions (normality). However, the results were back-transformed and presented in their original scales for the purpose of simplicity. As a subgroup analysis, we performed similar analyses among 180 participants with abnormal baseline values of TE (\geq 7 kPa) and CAP (\geq 238 dB/m) [28, 29].

 We firstly fitted the marginal models (unadjusted models) for each predictor variable to identify covariates that are marginally associated with each liver outcome variable at *p* < 0.10 (forward selection). Subsequently, multivariable models (adjusted models) included time, categorical

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 7

statistically significant when *p* < 0.05. All analyses were conducted using SAS version 9.4 (SAS

Institute, Inc., Cary, NC).

Sample Size Considerations

197 The sample size $(n = 46)$ was based on availability of data during the time span of the database

retrieval. A sample size of 46 yielded 85.7% statistical power to detect a large effect size

(Cohen's *f* = 0.5), determined by repeated measures ANOVA with a significance level of 0.05. A

statistical power calculation was performed in R version 4.0.2 (R Foundation for Statistical

Computing, Vienna, Austria).

Results

Demographic and Clinical Characteristics

The baseline characteristics are summarized in Table 1. The final data included 46 participants.

206 Overall, the mean age of study participants was 56.4 years (SD = 4.7 years). A majority of

participants were diagnosed with HIV (*n =* 28*;* 60.9%) and were either overweight (*n =* 15*;*

32.6%) or obese (*n =* 13*;* 28.3%). Most participants were Black (*n =* 35*;* 76.1%) and male sex (*n*

209 $= 29$; 63.0%). With 9 and 3 missing values, a majority of participants smoked cigarettes ($n = 30$;

- 210 81.1%) and were HCV negative $(n = 38; 88.4\%)$ at the time of enrollment in the 30-Day
- Challenge Study.
- 212 Approximately 20% of participants had mild ($n = 4$) or severe ($n = 5$) fibrosis and almost half (n
- 213 = 21; 45.6%) had steatosis. The majority of participants did not have fibrosis $(n = 27, 58.7\%)$
- based on FIB-4 index.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 8

215

216 **Table 1. Baseline characteristics of study participants in the study.**

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 9

- 217 Data reported as mean (SD) for continuous variables and frequencies with percentages for
- 218 categorical variables; $SD = standard deviation$.
- 219 Percentages may not add up to 100% due to rounding.
- 220 FIB-4 = Fibrosis-4 index; $SD =$ standard deviation.
- 221 $^{\circ}$ $^{\circ}$ S0: CAP < 238 dB/M; S1: 238 \leq CAP < 260 dB/M; S2: 260 \leq CAP < 293 dB/M; S3: CAP \geq 222 293 dB/M [30]
- 223 b No or mild scarring: $2 \leq TE < 7.1$ kPa; mild fibrosis: $7.1 \leq TE < 9.5$ kPa; severe fibrosis: TE \geq 224 9.5 kPa [30].
- 225 c Absence of fibrosis: FIB-4 < 1.45; inconclusive: $1.45 \leq$ FIB-4 \leq 3.25; severe fibrosis: FIB-4 > 226 3.25 [20].
- 227 d Underweight/normal: BMI < 25.0; overweight: $25.0 \leq$ BMI \leq 30.0; obese: BMI \geq 30.
- 228 $*$ 3 missing values; ** 9 missing values.
- 229

230 **Unadjusted Models for Screening Covariates (Forward Selection of**

231 **Model Covariates)**

- 232 In the unadjusted model using the entire sample, age (type III $p = 0.047$) and sex (type III $p =$
- 233 0.019) were marginally associated with the the change in CAP. None of the covariates were
- 234 significantly associated with changes in TE or FIB-4.
- 235
- 236 In the marginal analysis using subsamples with abnormal baseline TE, HCV (type III $p = 0.010$)
- 237 and sex (type III $p = 0.015$) were significantly associated with change in TE. There were
- 238 marginal associations between FIB-4 and HCV (type III $p = 0.080$). None of covariates were
- 239 significantly associated with change in CAP in this subsample.
- 240 With subsamples of abnormal baseline CAP, age (type III $p = 0.009$), HIV (type III $p = 0.052$),
- 241 and BMI (type III $p = 0.012$) were significantly associated with change in CAP. There was
- 242 significant marginal association between FIB-4 and BMI (type III $p = 0.009$). Lastly, TE did not
- 243 have marginal association with any covariates.
- 244
- 245 Subsequently, marginally significant covariates were included in the initial multivariable model
- 246 for the backward elimination.
- 247
- 248 **Adjusted Models for Liver Outcomes Using Entire Samples (***n* **= 46)**

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 10

249 The results presented in Table 2 indicate that there was no significant change in any of liver

250 outcomes for every one-day increase in time regardless of the level of alcohol intake (interaction

251 terms). Males had significantly smaller changes in levels of CAP ($\hat{\beta}$ = -22.90; 95% CI of $\hat{\beta}$: -

252 $41.49, -4.301$; $p = 0.017$), when compared to females. Older age was associated with greater

253 changes in levels of CAP ($\hat{\beta}$ = 2.489; 95% CI of $\hat{\beta}$: 0.538, 4.441; $p = 0.014$).

254

255 **Table 2. Changes in liver outcomes associated with changes in alcohol consumption at 30** 256 **and 90 days among 46 adults participating in a contingency management study.**

257 All mixed-effects models included linear function of time, categorical alcohol intake, and an

258 interaction term with categorical alcohol intake and time. An unstructured covariance structure 259 was used.

260 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the

261 coefficient estimates.

262 ^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor 263 for the fitted model for change in CAP as an outcome variable.

²⁶⁴ ^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex

265 were firstly considered as potential confounders and to be selected from unadjusted models at the

266 0.1 significance level. Selected covariates were then remained after backward elimination at the 267 0.05 significance level.

268 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 =

269 Fibrosis-4 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval

270 * A p-value < 0.05 was considered statistically significant, unless otherwise noted.

271 ‡ Reference group for comparisons.

272

273

274

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 11

275 **Adjusted Models for Liver Outcomes with Abnormal Baseline TE**

276 **Samples** $(n = 9)$

- 277 The interaction terms of the mixed-effects model results using samples with abnormal baseline
- 278 TE (Table 3) highlights that there were no significant changes in liver outcome measures with
- 279 varying alcohol intake categories for every one-day increase in time. Of them, the greater change
- 280 (increase) in FIB-4 from baseline for every one-day increase in time was observed for those who
- 281 quit or reduced drinking $(\exp(\hat{\beta}) = 1.010; 95\% \text{ CI of } \exp(\hat{\beta})$: 0.999, 1.021; $p = 0.067$), when
- 282 compared with continued heavy drinking, albeit not statistically significant. This implies that
- 283 34.8% higher level of FIB-4 in quit or reduced drinking versus continued heavy drinking after 30
- 284 days, calculated by $[\exp(30 * \hat{\beta})] * 100\%$.
- 285
- 286 Sex $(p = 0.229)$ and HCV $(p = 0.086)$ were excluded from the final adjusted model after the

287 backward elimination for TE. HCV was remained significant in the model for FIB-4 (*p* = 0.006)

288 after the backward elimination.

289

290 **Table 3. Changes in liver outcomes associated with changes in alcohol consumption at 30** 291 **and 90 days among 9 adults with abnormal baseline TE (TE** \geq **7) participating in a** 292 **contingency management study.**

293 All mixed-effects models included linear function of time, categorical alcohol intake, and an

294 interaction term with categorical alcohol intake and time. An unstructured covariance structure 295 was used.

296 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the

297 coefficient estimates.

298 ^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor

299 for the fitted model for change in CAP as an outcome variable.

 300 ^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex

301 were firstly considered as potential confounders and to be selected from unadjusted models at the

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 12

-
- 302 0.1 significance level. Selected covariate was then remained after backward elimination at the 303 0.05 significance level.
- 304 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 =
- 305 Fibrosis-4 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval.
- 306 * A p-value < 0.05 was considered statistically significant, unless otherwise noted.
- 307 ‡ Reference group for comparisons.

309 **Adjusted Models for Liver Outcomes with Abnormal Baseline CAP**

310 **Samples** $(n = 21)$

- 311 In the mixed-effects model using samples with abnormal baseline CAP (Table 4), there was no
- 312 statistically significant interaction effect of time and alcohol intake categories on changes in liver
- 313 outcome measures. Although it was not statistically significant, it is noteworthy that the greater
- 314 change (increase) in CAP from baseline for every one-day increase in time was observed for
- 315 those who quit or reduced drinking ($\hat{\beta} = 0.315$; 95% CI of $\hat{\beta}$: -0.588, 1.218; $p = 0.465$), when
- 316 compared with continued heavy drinking.
- 317

308

- 318 BMI remained in the final adjusted model for CAP and FIB-4 after backward elimination. Obese
- 319 (exp($\hat{\beta}$) = 1.285; 95% CI of exp($\hat{\beta}$): 1.079, 1.531; *p* = 0.009) participants had 28.5% significantly
- 320 higher level of FIB-4 from baseline, comparing with those who were either underweight or
- 321 normal. Lastly, HIV ($p = 0.174$) and age ($p = 0.066$) were excluded from the final adjusted
- 322 models for CAP after the backward elimination.

323 **Table 4. Changes in liver outcomes associated with changes in alcohol consumption at 30** 324 **and 90 days among 21 adults with abnormal baseline CAP (CAP** ≥ **238) participating in a** 325 **contingency management study.**

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 13

 All mixed-effects models included linear function of time, categorical alcohol intake, and an interaction term with categorical alcohol intake and time. An unstructured covariance structure was used. The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the coefficient 329 estimates.
330 $^{\circ}$ This is to

^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor for the fitted model for change in CAP as an outcome variable. fitted model for change in CAP as an outcome variable.

 ^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex were firstly considered as potential confounders and to be selected from unadjusted models at the 0.1 significance

- level. Selected covariates were then remained after backward elimination at the 0.05 significance level.
- TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 = Fibrosis-4

336 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval.
337 * A p-value < 0.05 was considered statistically significant, A p-value < 0.05 was considered statistically significant, unless otherwise noted.

 $\frac{1}{338}$ [†] A Bonferroni-corrected p-value of 0.0167 was considered statistically significant results for BMI.

‡ Reference group for comparison

Discussion

 To our knowledge, this study is the first of its kind in the literature to evaluate liver abnormalities before and after CM to reduce heavy drinking beyond 30-days of follow-up. To date, no studies

have examined whether reduction in drinking will have an effect in a population of persons

without severe liver disease to start with, but who are at high risk for progression. In this study,

the interaction term obtained in an analysis showed that there were no significant changes in

liver abnormalities after 90-days of drinking abstinence or reduction among heavy drinkers with

or without stratified TE and CAP values at baseline. This suggests that CM for drinking

reduction may not be effective at least short-term prospective in improving liver fibrosis and

steatosis for subjects with or without abnormal levels of TE or CAP. It is not surprising to see

that the behavioral intervention has not always been successful in improving health outcomes. A

recent study has shown that the dietary behavioral intervention to increase vegetable intake did

not significantly reduce cancer progression in men with early-stage prostate cancer [31]. In

addition, results of the meta-analysis suggested that a brief intervention on alcohol consumption

did not substantially reduce cigarette smoking in terms of frequency of smoking and likelihood

of smoking cessation [32]. Although we did not see an improvement in our study, it is

noteworthy that there was no significant change in liver abnormalities over time. Therefore, the

liver disease did not progress further stages. It remains a question whether our intervention is

what prevented the disease progression.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 14

 Additional findings of this study have identified a number of covariates that are significantly associated with liver outcome measures. Participants with HCV infection had substantially higher levels of FIB-4 with stratified TE values at baseline, when compared with those without HCV infection. It is important to note that none of the participants had advanced alcoholic liver disease or acute alcoholic hepatitis at the time of study enrollment. Moreover, the majority of the study participants were recruited from an HIV clinic, not a liver clinic. Thus, we may have less opportunities to view improvement in liver outcomes. This study has a number of limitations to be considered. First, the alcohol intake categories variable was created based on the TLFB method to calculate average number of drinks per week. A recall bias and social desirability bias in self-reported longitudinal number of drinks per day may lead to an inaccurate estimation of parameter estimates of the model. This may be especially true during the CM period, as contingencies were aligned with drinking abstinence. Second, although our results will contribute future understanding on changes in liver outcome measures, the fitted model was constructed using a dataset with a limited number of covariates and relatively small sample size. Future studies with a larger sample size and diverse cohort characteristics (*e.g.* adjusted

 FibroScan scores by GGT and lifestyle variable such as health satisfaction or well-being) are warranted to validate our findings.

Acknowledgments

 We are grateful for the administrative support of Dr. Christine Frank and for the data management support of Dr. Zhi Zhou and Mr. Alex Li at the Southern HIV and Alcohol Research Consortium.

References

 [1] O'Keefe JH, Bhatti SK, Bajwa A, DiNicolantonio JJ, Lavie CJ. Alcohol and cardiovascular health: the dose makes the poison…or the remedy. Mayo Clin Proc. 2014;89(3):382-93. doi: 10.1016/j.mayocp.2013.11.005. PMID: 24582196.

- [2] National Institute on Alcohol Abuse and Alcoholism (NIAAA). 2020. Alcohol and American
- Society: A Complex Relationship. [accessed 2023 February 27].
- [https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-impact-](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-impact-health)
- [health.](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-impact-health)
- [3] Rehm J, Shield KD. Global alcohol-attributable deaths from cancer, liver cirrhosis, and injury
- in 2010. Alcohol Res. 2013;35(2):174-83. PMID: 24881325.
- [4] Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic Liver Disease: Pathogenesis and
- Current Management. Alcohol Res. 2017;38(2):147-161. PMID: 28988570.
- [5] Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical
- perspective. Liver Res. 2018;2(4):161-172. doi: 10.1016/j.livres.2018.11.002. PMID: 31214376.
- [6] Traversy G, Chaput JP. Alcohol Consumption and Obesity: An Update. Curr Obes Rep.
- 2015;4(1):122-30. doi: 10.1007/s13679-014-0129-4. PMID: 25741455.
- [7] Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets.
- Gastroenterology. 2011;141(5):1572-85. doi: 10.1053/j.gastro.2011.09.002. PMID: 21920463.
- [8] Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for
- advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol.
- 2017;9(2):91-98. doi: 10.4254/wjh.v9.i2.91. PMID: 28144390.
- [9] Barve S, Kapoor R, Moghe A, Ramirez JA, Eaton JW, Gobejishvili L, Joshi-Barve S,
- McClain CJ. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver
- disease in HIV-infected patients. Alcohol Res Health. 2010;33(3):229-36. PMID: 23584064.
- [10] Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease:
- An update. Hepatology. 2015;62(6):1871-82. doi: 10.1002/hep.28150. PMID: 26340591.
- [11] Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, Kopec J,
- Montaner JSG, Hogg RS, Lima VD. Excess burden of age-associated comorbidities among
- people living with HIV in British Columbia, Canada: a population-based cohort study. BMJ
- Open. 2021;11(1):e041734. doi: 10.1136/bmjopen-2020-041734. PMID: 33419911.
- [12] Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors
- of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017;31(11):1621-1632. doi:
- 10.1097/QAD.0000000000001504. PMID: 28398960.
- [13] Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient
- Care STDS. 2005;19(6):356-65. doi: 10.1089/apc.2005.19.356. PMID: 15989431.

- [14] Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. BMJ
- Open Gastroenterol. 2017;4(1):e000166. doi: 10.1136/bmjgast-2017-000166. PMID: 29119002.
- [15] Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol Use and Human
- Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future
- Directions. Alcohol Clin Exp Res. 2016;40(10):2056-2072. doi: 10.1111/acer.13204. PMID:
- 27696523.
- [16] Dougherty DM, Hill-Kapturczak N, Liang Y, Karns TE, Cates SE, Lake SL, Mullen J,
- Roache JD. Use of continuous transdermal alcohol monitoring during a contingency
- management procedure to reduce excessive alcohol use. Drug Alcohol Depend. 2014;142:301-
- 306. doi: 10.1016/j.drugalcdep.2014.06.039. PMID: 25064019.
- [17] Barnett NP, Celio MA, Tidey JW, Murphy JG, Colby SM, Swift RM. A preliminary
- randomized controlled trial of contingency management for alcohol use reduction using a
- transdermal alcohol sensor. Addiction. 2017;112(6):1025-1035. doi: 10.1111/add.13767. PMID:
- 28107772.
- [18] Mehta G, Macdonald S, Cronberg A, Rosselli M, Khera-Butler T, Sumpter C, Al-Khatib S,
- Jain A, Maurice J, Charalambous C, Gander A, Ju C, Hakan T, Sherwood R, Nair D, Jalan R,
- Moore KP. Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver
- function tests and cancer-related growth factors: a prospective observational study. BMJ Open.
- 2018;8(5):e020673. doi: 10.1136/bmjopen-2017-020673. PMID: 29730627.
- [19] Munsterman ID, Groefsema MM, Weijers G, Klein WM, Swinkels DW, Drenth JPH,
- Schellekens AFA, Tjwa ETTL. Biochemical Effects on the Liver of 1 Month of Alcohol
- Abstinence in Moderate Alcohol Consumers. Alcohol Alcohol. 2018;53(4):435-438. doi:
- 10.1093/alcalc/agy031. PMID: 29726886.
- [20] Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M,
- Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical
- Investigators. Development of a simple noninvasive index to predict significant fibrosis in
- patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25. doi: 10.1002/hep.21178.
- PMID: 16729309.
- [21] Witkiewitz K, Kranzler HR, Hallgren KA, O'Malley SS, Falk DE, Litten RZ, Hasin DS,
- Mann KF, Anton RF. Drinking Risk Level Reductions Associated with Improvements in

- Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcohol Clin
- Exp Res. 2018;42(12):2453-2465. doi: 10.1111/acer.13897. PMID: 30395350.
- [22] Henssler J, Müller M, Carreira H, Bschor T, Heinz A, Baethge C. Controlled drinking-non-
- abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-
- analysis and meta-regression. Addiction. 2021;116(8):1973-1987. doi: 10.1111/add.15329.
- PMID: 33188563.
- [23] Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline
- Followback when administered by telephone and by computer. Drug Alcohol Depend.
- 1996;42(1):49-54. doi: 10.1016/0376-8716(96)01263-x. PMID: 8889403.
- [24] National Institute on Alcohol Abuse and Alcoholism (NIAAA). 2021. Rethinking drinking:
- Alcohol and your health. [accessed 2023 February 10].
- https://www.niaaa.nih.gov/sites/default/files/publications/NIAAA_RethinkingDrinking.pdf
- [25] Silverstein PS, Kumar S, Kumar A. HIV-1, HCV and alcohol in the CNS: potential
- interactions and effects on neuroinflammation. Curr HIV Res. 2014;12(4):282-92. doi:
- 10.2174/1570162x12666140721122956. PMID: 25053363.
- [26] National Heart, Lung, and Blood Institute (NHLBI). 2013. Managing overweight and
- obesity in Adults: systematic evidence review from the obesity expert panel. [accessed 2023
- February 8]. [https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-](https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-review.pdf)
- [review.pdf.](https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-review.pdf)
- [27] Loomis AK, Kabadi S, Preiss D, Hyde C, Bonato V, St Louis M, Desai J, Gill JM, Welsh P,
- Waterworth D, Sattar N. Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two
- Electronic Health Record Prospective Studies. J Clin Endocrinol Metab. 2016;101(3):945-52.
- doi: 10.1210/jc.2015-3444. PMID: 26672639.
- [28] Scheiner B, Steininger L, Semmler G, Unger LW, Schwabl P, Bucsics T, Paternostro R,
- Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Controlled attenuation parameter does not
- predict hepatic decompensation in patients with advanced chronic liver disease. Liver Int.
- 2019;39(1):127-135. doi: 10.1111/liv.13943.PMID: 30107095.
- [29] Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in
- Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5):1264-1281.e4.
- doi: 10.1053/j.gastro.2018.12.036. PMID: 30660725.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES 18

- [30] Sansom SE, Martin J, Adeyemi O, Burke K, Winston C, Markham S, Go B, Huhn G.
- Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation
- Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency
- Virus/HCV Coinfection in a Large US Hepatitis Clinic. Open Forum Infect Dis.
- 2019;6(4):ofz099. doi: 10.1093/ofid/ofz099. PMID: 30968054.
- [31] Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK,
- Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L,
- Small EJ, Morris MJ, Pierce JP, Marshall J. Effect of a Behavioral Intervention to Increase
- Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer:
- The MEAL Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):140-148. doi:
- 10.1001/jama.2019.20207. PMID: 31935026; PMCID: PMC6990696.
- [32] McCambridge J, Jenkins RJ. Do brief interventions which target alcohol consumption also
- reduce cigarette smoking? Systematic review and meta-analysis. Drug Alcohol Depend. 2008
- Aug 1;96(3):263-70. doi: 10.1016/j.drugalcdep.2008.03.011. Epub 2008 May 23. PMID:

18457926.

Supporting Information

 S1 Table. Crude descriptive statistics of liver outcome measures at baseline, 30-days, and 90-days.

- **S2 Table. Descriptive statistics of change in liver outcome measures at 30-days and 90-days**
- **with quit/reduced and continued heavy drinking.**
-
- **S3 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30**
- **and 90 days among 46 adults participating in a contingency management study.**

- **S4 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30**
- **and 90 days among 9 adults with abnormal baseline TE (TE** ≥ **7) participating in a**
- **contingency management study.**

- 512 **S5 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30**
- 513 **and 90 days among 21 adults with abnormal baseline CAP (CAP** ≥ **238) participating in a**
- 514 **contingency management study.**

. FibroScan conducted